Surgery Partners Advances $1.15 Billion Asset Sale to Intermountain Health With Binding Escrow Agreement

Transaction Structure and Escrow Mechanics

On July 21, 2026, Surgery Partners and Intermountain Health executed a structured transaction framework centered on an escrow mechanism designed to protect both parties' interests during the approval phase. The binding agreement places signature pages for two separate Securities Purchase Agreements into escrow, with release of those signatures contingent upon satisfaction of specific conditions. This escrow approach allows the parties to maintain a firm contractual commitment while permitting additional time for internal governance processes and regulatory reviews to proceed.

The escrow will be released only after Mountain View Hospital's physician members and physician governing board provide their requisite approvals of the transaction. Additionally, Surgery Partners must certify to Intermountain Health that the representations and warranties in the Agreements remain accurate as of the release date and that no material facts have emerged since escrow placement that would necessitate new or modified disclosures to the seller's disclosure schedules. Should such disclosures become required, they must be acceptable to all parties before release occurs. This two-part conditional mechanism reflects the complex stakeholder landscape inherent in hospital asset sales, particularly where physician ownership interests remain involved.

Valuation Framework and Expected Proceeds

The combined facilities—Mountain View Hospital, LLC and Idaho Falls Community Hospital, LLC—carry a total transaction value of approximately $1.15 billion under the proposed sale to Intermountain Health. Surgery Partners is positioned to receive total consideration of approximately $795 million from this transaction, representing the company's gross proceeds before customary purchase price adjustments. These adjustments are expected to include modifications related to indebtedness carried by the divested entities, working capital balances as of the closing date, transaction expenses incurred in connection with the sale, and other standard closing items typical of healthcare asset transactions.

The disclosure filing makes clear that Surgery Partners cannot provide a reasonable estimate of final net cash proceeds at the present time, given the uncertainty surrounding the magnitude of these purchase price adjustments. This caveat underscores the material impact that debt repayment obligations, working capital normalization, and closing costs may exert on the ultimate cash flow to the company. Investors assessing the transaction's financial benefit to Surgery Partners should account for this significant range of potential adjustment outcomes as the transaction progresses toward closing.

Hospital Asset Portfolio and Physician Ownership Preservation

The divested assets comprise two interconnected hospital operations located in Idaho. Mountain View Hospital and Idaho Falls Community Hospital, along with their respective subsidiaries, represent core components of Surgery Partners' hospital operations segment. The transaction structure preserves an important stakeholder relationship: physician ownership of Mountain View Hospital will remain unchanged despite the sale of Surgery Partners' ownership interests to Intermountain Health. This continuity of physician governance reflects negotiated terms that recognize the centrality of physician leadership and investment in the hospital's operations and strategic direction.

By maintaining physician ownership stakes while transferring Surgery Partners' interests to Intermountain Health, the transaction architecture attempts to balance the acquirer's ownership consolidation with the retention of physician-leadership participation. This approach may mitigate potential disruption to clinical operations and physician relationships during the transition. However, the requirement to obtain formal physician member and governing board approvals before escrow release indicates that this constituency holds meaningful veto power over transaction completion, adding an additional approval layer beyond traditional regulatory pathways.

Regulatory and Closing Condition Requirements

The transaction's completion remains contingent on satisfaction of multiple regulatory and contractual conditions that extend beyond the escrow release mechanics. Foremost among these is the requirement to obtain clearance under the Hart-Scott-Rodino Act, the federal premerger notification regime administered by the Federal Trade Commission and Department of Justice. Given the healthcare sector's regulatory sensitivity and the size of this transaction, Hart-Scott-Rodino review may entail substantive competitive analysis and potentially second-request interrogatories that could extend the approval timeline. The filing specifies that expiration of applicable Hart-Scott-Rodino waiting periods is a closing condition, meaning the transaction cannot close until federal premerger review is complete.

Beyond Hart-Scott-Rodino clearance, the parties must secure any other applicable material regulatory approvals, which in the healthcare context may include state-level hospital licensing authorities, state attorney general review, state health department approvals, and potentially state insurance commissioner review depending on the nature of any related insurance arrangements. Additionally, the transaction requires certain material third-party consents, though the filing does not enumerate the specific third parties or consent categories involved. These third-party consents could encompass payer contracts, physician service agreements, equipment leases, facility licenses, or other operational arrangements material to the divested hospitals' functioning. The breadth of these closing conditions signals that securing all necessary approvals represents a material execution risk for transaction completion.

Outside Termination Date and Extension Provisions

The definitive Agreements establish an outside termination date set at sixty days following the date on which signature pages are released from escrow. This termination date represents an absolute deadline for transaction closing, beyond which either Surgery Partners or Intermountain Health may terminate the agreement without continuing to pursue regulatory approvals or closing conditions. However, the filing indicates that this sixty-day outside date is subject to extension in certain circumstances, though the specific circumstances permitting extension are not detailed in the current disclosure. The ability to extend the outside date may prove critical if regulatory review processes, particularly Hart-Scott-Rodino examination, require additional time beyond initial projections.

The presence of an outside termination date and extension mechanisms provides both parties with contractual certainty while preserving flexibility for regulatory processes that may not align with compact timelines. For Surgery Partners shareholders, the outside date represents a meaningful checkpoint by which transaction completion or material delays should become apparent. The company's inability to commit to a firm closing timeline at this stage reflects the genuine uncertainty inherent in regulatory approval processes for healthcare transactions of this magnitude, particularly in sectors where state and federal authorities maintain overlapping jurisdictional interests.

Representations, Warranties, and Indemnification Structures

The Securities Purchase Agreements incorporate customary representations and warranties from both Surgery Partners and Intermountain Health regarding the divested assets' legal, financial, and operational status. These representations address typical transaction domains, including but not limited to the legality of the entities, absence of material undisclosed liabilities, compliance with healthcare regulations, and accuracy of financial information provided during diligence. The Agreements also specify defined covenants—obligations binding the parties during the pre-closing period—that likely address continuity of operations, maintenance of existing relationships with payors and providers, and restrictions on material changes to the business pending closing.

The indemnification provisions referenced in the filing establish the mechanism by which one party may recover losses from the other should breaches of representations, warranties, or covenants occur. Such indemnification typically operates through escrow holdback arrangements, where a portion of purchase price proceeds is held in trust for a defined period (often twelve to twenty-four months post-closing) to fund any valid indemnification claims. The specific scope, survival periods, baskets, and caps on indemnification liability are material terms that, while not detailed in this announcement, are negotiated provisions that allocate post-closing risk between buyer and seller. Understanding these terms becomes relevant to investors assessing Surgery Partners' residual liability exposure following closing.

Strategic Context and Divestiture Rationale

Surgery Partners' decision to divest Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health occurs within the broader healthcare consolidation landscape, where smaller independent operators increasingly face pressure to align with larger health systems or exit specific markets. The transaction represents a deliberate portfolio management action, transferring these two interconnected Idaho properties to a significant regional healthcare system with deeper operational scale and capital resources. For Surgery Partners, this divestiture generates substantial liquidity—approximately $795 million in gross proceeds before adjustments—that the company may deploy toward debt reduction, remaining operations enhancement, or strategic acquisitions in markets where Surgery Partners maintains competitive advantages.

The sale also reflects Intermountain Health's strategy of geographic and operational expansion, positioning the acquirer to enhance its footprint in the Mountain West region. By acquiring these facilities, Intermountain Health integrates additional hospital capacity and associated service lines into its integrated health system, potentially enabling economies of scope through consolidated procurement, shared clinical services, and unified payer contracting. For Surgery Partners, the transaction offers an exit from Idaho markets while preserving physician ownership stakes that may facilitate smoother post-closing transitions and maintain relationships with key clinical stakeholders.

Post-Announcement Disclosures and Regulatory Filings

On July 24, 2026, three days after the escrow placement, Surgery Partners issued a press release announcing the entry into the binding agreement for sale of its Idaho facilities to Intermountain Health. This public announcement, filed as Exhibit 99.1 to the company's current report disclosure, simultaneously satisfied the company's obligation to make material information available to the investing public while adhering to Securities and Exchange Commission disclosure timing requirements. The filing itself notes that the press release content and this current report are furnished for Regulation FD purposes, meaning they are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act and do not trigger the liabilities associated with filed documents.

The distinction between furnished and filed disclosures carries technical implications for the enforceability of statements and the liability exposure of company officers and directors. By characterizing this announcement as a Regulation FD disclosure rather than a Section 18 filing, Surgery Partners provides comprehensive transparency regarding the transaction while limiting potential securities law liability for forward-looking statements or projections contained in the press release. This regulatory approach is standard practice for material event announcements and reflects the company's navigation of disclosure obligations across multiple securities law frameworks.

Timeline, Approvals, and Investor Milestones

The transaction has established several critical junctures that investors should monitor as execution progresses. The immediate near-term milestone is release of signature pages from escrow, contingent on physician approvals and representation accuracy certification. Following escrow release, the sixty-day (extendable) outside closing date becomes operative, establishing a clear temporal boundary for regulatory clearance and final closing. Within this period, Hart-Scott-Rodino review must conclude, state and federal regulatory approvals must be obtained, and material third-party consents must be secured. Each of these approval stages presents execution risk that could result in either timely closing or unexpected delays that extend beyond current expectations.

Investors tracking Surgery Partners' progress should monitor developments regarding physician member and governing board approvals at Mountain View Hospital, as delays or complications at this governance level could impede movement toward escrow release. Separately, announcements regarding Hart-Scott-Rodino status—including any requests for additional information or second requests—will signal the federal premerger review process's trajectory. Public announcements regarding state regulatory clearance, third-party consents, and ultimate closing completion will provide visible confirmation that the transaction is progressing toward finalization. The company's quarterly and annual filings subsequent to this announcement will incorporate updated disclosures regarding transaction status, expected closing timing, and any material changes to transaction terms or conditions.

Financial and Strategic Implications for Surgery Partners Shareholders

The $795 million in gross proceeds (before purchase price adjustments) will materially impact Surgery Partners' balance sheet and capital allocation strategy upon closing. The magnitude of this transaction—valued at approximately $1.15 billion for the combined facilities—suggests these assets represent a substantial portion of Surgery Partners' hospital operations portfolio. The capital proceeds from this sale position the company to accelerate debt reduction, invest in growth initiatives within remaining markets, fund shareholder returns through dividends or buybacks, or pursue strategic acquisitions that strengthen Surgery Partners' competitive position in healthcare services. The company's management and board will face material decisions regarding capital deployment once net proceeds are received.

From a strategic standpoint, the divestiture signals Surgery Partners' prioritization of markets or operational segments where the company possesses competitive advantages or growth potential, relative to the Idaho markets being transferred to Intermountain Health. This disciplined portfolio management approach—divesting non-core or lower-return assets to more formidable regional competitors while retaining and investing in higher-potential operations—aligns with financial best practices in healthcare services consolidation. For investors evaluating Surgery Partners' long-term trajectory, the transaction provides visibility into management's strategic priorities and willingness to execute meaningful portfolio adjustments in response to market dynamics and competitive pressures.